Abstract
Background: The majority of reported cancer survival statistics in the United States are generated using the National Cancer Institute's publicly available Surveillance, Epidemiology, and End Results (SEER) data, which prior to 2019 represented 28% of the US population (now 37%). In the case of rare cancers or special subpopulations, data sets based on a larger portion of the US population may contribute new insights into these low-incidence cancers. The purpose of this study is to characterize the histology-specific survival patterns for all primary malignant and nonmalignant primary brain tumors in the United States using the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR). Methods: Survival data were obtained from the NPCR (includes data from 39 state cancer registries, representing 81% of the US population). Relative survival rates (RS) with 95% CI were generated using SEER∗Stat 8.3.5 from 2004 to 2014 by behavior, histology, sex, race/ethnicity, and age at diagnosis. Results: Overall, there were 488 314 cases from 2004 to 2014. Overall 5-year RS was 69.8% (95% CI = 69.6%-69.9%). Five-year RS was 35.9% (95% CI = 35.6%-36.1%) for malignant and 90.2% (95% CI = 90.1%-90.4%) for nonmalignant tumors. Pilocytic astrocytoma had the longest 5-year RS (94.2%, 95% CI = 93.6%-94.6%) of all glioma subtypes, whereas glioblastoma had the shortest 5-year RS (6.1%, 95% CI = 6.0%-6.3%). Nonmalignant nerve sheath tumors had the longest 5-year RS (99.3%, 95% CI = 99.1%-99.4%). Younger age and female sex were associated with increased survival for many histologies. Conclusions: Survival after diagnosis with primary brain tumor varies by behavior, histology, and age. Using such a database that includes more than 80% of the US population may represent national survival patterns.
Original language | English (US) |
---|---|
Pages (from-to) | 306-312 |
Number of pages | 7 |
Journal | Neuro-Oncology Practice |
Volume | 7 |
Issue number | 3 |
DOIs | |
State | Published - Jun 5 2020 |
Funding
This work was supported by a Research Training Grant from the Cancer Prevention and Research Institute of Texas [grant number RP160097T to QTO]. Funding for the Central Brain Tumor Registry of the United States was supported by the Centers for Disease Control and Prevention [CDC, contract No. 2016-M-9030], the American Brain Tumor Association, The Sontag Foundation, Novocure, Abbvie, the National Cancer Institute [NCI, contract No. HHSN261201800176P], the Musella Foundation, National Brain Tumor Society, the Children’s Brain Tumor Foundation, the Uncle Kory Foundation, and the Zelda Dorin Tetenbaum Memorial Fund, as well as private and in-kind donations. The findings and conclusions in this report are those of the authors and do not necessarily reflect the official position of the CDC or the NCI.
Keywords
- National Program of Cancer Registries (NPCR)
- United States
- United States Cancer Statistics (USCS)
- brain and CNS tumors
- relative survival
ASJC Scopus subject areas
- Neurology
- Oncology
- Medicine (miscellaneous)